Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
State Street SPDR S&P Biotech ETF
(NY:
XBI
)
123.11
+1.06 (+0.87%)
Streaming Delayed Price
Updated: 12:27 PM EST, Dec 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about State Street SPDR S&P Biotech ETF
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’
↗
June 11, 2025
Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.
Via
Stocktwits
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation
↗
May 30, 2025
Summit now intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration seeking approval for Ivonescimab plus chemotherapy based on the results of the trial.
Via
Stocktwits
Topics
Lawsuit
Regulatory Compliance
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence
↗
May 29, 2025
The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share.
Via
Stocktwits
Hedge Funds Are Building A Towering Wall Of Bets Against Stocks
↗
May 21, 2025
After a sharp 23% rebound in the S&P 500 since April, hedge funds are now stacking record levels of bearish bets against stocks as investors question the staying power of the tariff-relief rally.
Via
Benzinga
Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work
↗
May 20, 2025
The Trump administration unveiled the first details Tuesday on how it plans to lower drug prices "drastically" in the U.S.
Via
Investor's Business Daily
Topics
ETFs
Government
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
↗
May 19, 2025
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.
Via
Benzinga
Best Biotech Stocks to Buy in 2025
May 13, 2025
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.
Via
MarketBeat
Topics
ETFs
Economy
Government
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode
↗
May 09, 2025
The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024.
Via
Stocktwits
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
↗
May 07, 2025
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Via
Benzinga
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic
↗
May 05, 2025
The U.S. FDA stated that its review committee has identified no significant deficiencies and is on track to make a decision on the application by its deadline of the end of August.
Via
Stocktwits
Topics
Economy
Government
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
↗
April 28, 2025
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
↗
April 25, 2025
The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.
Via
Stocktwits
Topics
Artificial Intelligence
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated
↗
April 21, 2025
Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company.
Via
Stocktwits
Topics
Government
Retirement
Stocks
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic
↗
April 17, 2025
The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.
Via
Stocktwits
Topics
Bankruptcy
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
↗
April 10, 2025
Via
The Motley Fool
Topics
ETFs
Is It A Good Time To Trade Small Cap Biotech Stocks? - 3 Steps To Consider
↗
April 07, 2025
Large cap healthcare stocks have outperformed other sectors during the 2025 Tariff induced sell-off but they still have risks as one can see by Friday’s 5% decline.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Biotech Weakness Ahead?
↗
April 02, 2025
Out of 50,000 posts, I’m not sure I’ve ever mentioned the sector fund XBI before, but here we are. It seems to me that this fund, representing the biotech sector, is in for some serious skidding.
Via
Talk Markets
Topics
ETFs
Biotech Stocks Dive After Trump Tacks On 20% European Tariff. Why AbbVie, Merck Could Be Exposed.
↗
April 02, 2025
It's unclear whether pharmaceutical goods could be exempt from tariffs. A number of drugmakers manufacture ingredients abroad.
Via
Investor's Business Daily
Topics
Economy
Government
World Trade
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
↗
April 02, 2025
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.
Via
Stocktwits
Topics
ETFs
Government
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
↗
April 01, 2025
Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles.
Via
Investor's Business Daily
Topics
Workforce
Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
↗
March 31, 2025
Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration.
Via
Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
↗
March 31, 2025
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.
Via
Investor's Business Daily
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks
↗
March 27, 2025
The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025.
Via
Stocktwits
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up
↗
March 21, 2025
Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.
Via
Stocktwits
Capricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More Bullish
↗
March 20, 2025
The company said its available cash, cash equivalents, and marketable securities will be sufficient to cover the expenses and capital requirements into 2027.
Via
Stocktwits
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon
↗
March 19, 2025
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.
Via
Stocktwits
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
↗
March 18, 2025
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.
Via
Stocktwits
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled
↗
March 10, 2025
Small caps took another step down this past week as geopolitical events dampened sentiment.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?
↗
March 10, 2025
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.
Via
Stocktwits
Healthcare Sector Trying To Bounce Back
↗
March 09, 2025
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.